Spotlight Growth
No Result
View All Result
Wednesday, March 22, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

CTI BioPharma (NASDAQ: CTIC) Receives FDA Approval For VONJO to Treat Adult Myelofibrosis and Thrombocytopenia

by admin
March 1, 2022
in Bio/Med/Pharma
0
CTI BioPharma NASDAQ CTIC FDA Approval VONJO Spotlight Growth

CTI BioPharma NASDAQ CTIC FDA Approval VONJO Spotlight Growth

CTI BioPharma Corp. (NASDAQ: CTIC) is a commercial-stage biopharmaceutical company, which is focused on the research, acquisition, development, and commercialization of novel therapies for blood cancers. Shares of the biopharma company are jumping 43% through early trading on Tuesday, March 1, 2022. Over the past three months, CTI BioPharma has seen average daily volume of 2.11 million shares. However, volume of 56.28 million shares or dollar volume of around $150.27 million, has already exchanged hands through early trading.

Shares of CTI BioPharma are rallying after the company announced that the U.S. Food and Drug Administration has given accelerated approval of VONJO for the treatment of myelofibrosis and thrombocytopenia in adult patients. The approval makes VONJO the first approved therapy specifically to treat adult cytopenic myelofibrosis patients.

The FDA granted accelerated approval for VONJO after reviewing the efficacy results from the pivotal Phase 3 PERSIST-2 study in patients with myelofibrosis. Patients were randomly given VONJO 200mg twice daily (BID), VONJO 400mg once per day (QD), or the best available therapy (BAT). “In this study, in the cohort of patients with baseline platelet counts below 50 × 109/L who were treated with pacritinib 200 mg BD, 29% of patients had a reduction in spleen volume of at least 35% compared to 3% of patients receiving best available therapy, which included ruxolitinib,” according to CTI BioPharma’s press release.

As a condition of its accelerated approval, CTI BioPharma will be required to provide clear clinical benefits in a confirmatory trial. To complete this, the company says they expect to complete the PACIFICA trial with results sometime in mid-2025.

The FDA approval of VONJO also triggers a $60 million royalty from DRI Healthcare Trust, based upon the terms of its debt and royalty transaction. The proceeds are set to be used to help fund the official launch of VONJO.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

Tags: biopharmaceuticalsbiotechclinical trialscommon stockCTI BioPharmaCTICCTIC stockday tradingDRI Healthcare Trustemerging growthFDAFDA approvalhealth stockshealthcareinvestinginvestmentmedicalmicrocap stocksmyelofibrosismyelofibrosis treatmentNASDAQnewspharmaceuticalspublic companyRobinhoodrobinhood stockssalesservicessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstocksstocks to watchtradingtreatment
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
U.S. Xpress NYSE USX Knight-Swift Transportation NYSE KNX Acquisition Spotlight Growth

U.S. Xpress Enterprises (NYSE: USX) Enters Into Acquisition Agreement With Knight-Swift Transportation (NYSE: KNX) Valued at $808 Million

March 21, 2023
Axon Enterprise Logo

Axon Enterprise (NASDAQ: AXON) Maintains its Market Dominance with Strong Growth

March 20, 2023
PureCycle Technologies NASDAQ PCT PureFive Distribution Agreement Formerra Spotlight Growth

PureCycle Technologies (NASDAQ: PCT) Enters Into Strategic Distribution Partnership With Formerra For its PureFive UPR Polypropylene Resin Product

March 16, 2023
Why Investors Are Worried About Credit Suisse NYSE CS Spotlight Growth

Why Are Investors Worried About Credit Suisse (NYSE: CS)?

March 15, 2023

Recent News

U.S. Xpress NYSE USX Knight-Swift Transportation NYSE KNX Acquisition Spotlight Growth

U.S. Xpress Enterprises (NYSE: USX) Enters Into Acquisition Agreement With Knight-Swift Transportation (NYSE: KNX) Valued at $808 Million

March 21, 2023
Axon Enterprise Logo

Axon Enterprise (NASDAQ: AXON) Maintains its Market Dominance with Strong Growth

March 20, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested